Dr. Thomas Franke
Icahn School of Medicine
at Mt. Sinai
1425 Madison Avenue
New York, NY, 10029
Interested in becoming a member of the ACS?
American Chemical Society
New York Section, Inc.
Department of Chemistry
St. John's University
8000 Utopia Parkway
Jamaica, NY 11439
The Biochemical Topical Group collaborates with the Biochemical Pharmacology Discussion Group (BPDG) of
The New York Academy of Sciences (NYAS) to advance our knowledge of the activity and metabolism of
small compounds and biologics. The BPDG represents a diverse group of scientists with interests in biochemistry,
drug discovery, drug therapy, biomedical research, and related areas. Members are from pharmaceutical and biotechnology companies,
and academic institutions. Our purpose is to bring together diverse institutions and communities, industrial and academic researchers, lay-people
and experts to share exciting new findings and trends at the frontiers of drug research, development and application.
Each spring, BPDG issues a proposal request for symposia to be held at the NYAS. Topics that will be considered include chemotherapy,
neuropharmacology, antimicrobials, inflammation, drug discovery, pharmacology and toxicology.
Successful proposals are selected by a Steering Committee and 7-8 receiving the most votes
will constitute the next year's program. Selected symposia are held at 7 World Trade Center as half- or full-day events.
Lunch, coffee breaks and other networking opportunities at the symposia facilitate interactions and enable conversations.
February 20, 2018 Translational Approaches for Human Liver Disease
This symposium will explore emerging in vitro models for non-alcoholic steatohepatitis (NASH) to bridge the gap between existing preclinical animal models and human liver disease.
9:00 AM - 5:00 PM EDT
Non-alcoholic steatohepatitis (NASH) is the second leading cause of disease driving the need for liver transplantation in the United States with no approved treatments currently available. While a number of clinical approaches are under investigation, historically many promising drug candidates have not demonstrated clinical benefit, in part due to an over-reliance on animal models.
In vitro approaches that incorporate primary human cell types to model disease have the potential to improve clinical success by bridging the gap from preclinical animal models to patients. This symposium will present cutting-edge research highlighting current and emerging in vitro model systems, covering potential benefits and limitations for the treatment of liver disease.
March 19, 2018 Cell Death Pathways in Human Health and Disease
This symposium will explore the physiological processes by which cell death contributes to human disease, outlining mechanisms of cell clearance, impact on pathogenesis, and implication for therapeutics.
12:00 PM - 5:00 PM EDT
Cell death is a key driver of human disease. Processes linked to cell death, such as autophagy, further impact immune function, compounding disease pathology. Non-apoptotic cell death modalities (pyroptosis and necroptosis) are currently being investigated as opportunities for therapeutic intervention; however, the molecular pathways and physiological mechanisms controlling the dysfunction are ill-defined. In order to address this important knowledge gap, this symposium will present breaking research mapping the mechanisms by which cell death contributes to homeostasis and human disease, including mechanisms of cell clearance, the impact on pathogenesis and the implication for therapeutics.
April 17, 2018 Advances in Translational Models to Study Fibrosis
This symposium will review what is known about the cell and molecular biology of fibrosis and reparative healing, discuss current model systems, and consider the challenges and opportunities for future innovation.
12:00 PM - 5:00 PM EDT
Fibrosis is a common pathology in many chronic diseases and is often associated with disease progression. Many extracellular matrix macromolecules, as well as their regulators and modifiers have been identified as potential disease targets or biomarkers by extensive studies in numerous preclinical animal models of fibrosis. However, therapeutics development depends on in vitro experimental systems that model pathological processes in order to build assays for screening, mechanistic characterization and target disease link evaluation. In vitro fibrosis experimental systems have been limited, but a better understanding of shared pathways and the distinctions that lead to fibrosis in different organs is now emerging from technical advances such as proteomics, RNAseq, laser capture microdissection and the availability of clinical materials. The advent of engineered substrata with defined biomechanical properties, the use of stem cells and capabilities for genetic modification have also contributed to the design of increasingly sophisticated in vitro models of fibrosis. When coupled with co-culture and organoid technologies, these advances enable modeling of cell and tissue interactions in normal and fibrotic settings. This symposium will review what is known about the cell and molecular biology of fibrosis and reparative healing, discuss current model systems, and consider the challenges and opportunities for future innovation.
May 22, 2018 Thinking Outside the ATP Box: New Ways to Target Kinases for Therapeutics
This symposium will explore new and emerging technologies driving the advancement of drug development pipelines targeting kinase inhibitors.
12:00 PM - 5:00 PM EDT
Over the past few years we have witnessed considerable progress in the field of kinase inhibitors, however there is still no consensus as to which screening methods are best suited to their identification. This symposium will bring together experts in the field of kinase drug discovery to review the landscape, exploring new approaches and technologies driving the advancement of non-classical kinase inhibitor pipeline, and drawing on past lessons to provide insight into the future direction of the field.
September 25, 2018 Neuro-Immunology: The Impact of Immune Function in Alzheimer's Disease
This one-day symposium will build upon genetic evidence for inflammation in Alzheimer's Disease (AD), highlighting cutting-edge science that explores the mechanisms that underlie this intersection between neurology and immunology, and parse the contributions of the immune system to the range of behaviors evidenced over the clinical course of AD.
October 23, 2018 New Therapeutic Strategies to Combat Antibacterial Resistance
This symposium will focus on the current challenges that basic and translational researchers are facing to fight antimicrobial resistance, as well as offering perspectives on emerging therapeutic strategies to address this global health threat.
December 4, 2018 Phagocytes in Health and Disease
This symposium will bring together leaders in the fields of immunology, cancer biology and tissue regeneration to highlight emerging roles for phagocytes in health and disease and develop new conceptual frameworks to integrate macrophage and dendritic cell functions with mammalian development, physiology and tissue biology.
Topical Groups & Committees:
New York Section
Support Your Local Section